Zeltia Group Says in Advanced Talks to License Aplidin

October 24, 2008 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

MADRID, Oct 24 (Reuters) -Spanish biotechnology firm Zeltia is in advanced talks to license Aplidin in the United States and the rest of the world, with the exception of Europe, where it will license the drug on its own, the company said on Friday.

Twitter
LinkedIn
Facebook
Email
Print

Alliances Europe